Recent

% | $
Quotes you view appear here for quick access.

Celgene Corporation Message Board

  • winsor20007 winsor20007 Feb 11, 2013 10:36 AM Flag

    More good news for CELGENE: Pomalyst could be its next blockbuster drug topping $5 billion in total annual sales.

    Celgene thinks that Pomalyst could be its next blockbuster drug. It has good reason to have high hopes. Some estimates count around 45,000 multiple myeloma patients in the U.S. and Europe who failed two prior therapies. Considering that Kyprolis is priced at $10,000 per 28-day cycle and Pomalyst is expected to be priced a little higher than that, the market represents an opportunity topping $5 billion in total annual sales.

    Sentiment: Strong Buy

 
CELG
102.45+2.86(+2.87%)Feb 12 4:00 PMEST